Coeptis Therapeutics (COEP) Competitors $12.27 +0.38 (+3.20%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$12.14 -0.13 (-1.03%) As of 09/5/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. IMMP, EDIT, TKNO, FENC, ALEC, ANNX, HUMA, PRQR, SGMT, and AVTEShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Prima BioMed (IMMP), Editas Medicine (EDIT), Alpha Teknova (TKNO), Adherex Technologies (FENC), Alector (ALEC), Annexon (ANNX), Humacyte (HUMA), ProQR Therapeutics (PRQR), Sagimet Biosciences (SGMT), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Its Competitors Prima BioMed Editas Medicine Alpha Teknova Adherex Technologies Alector Annexon Humacyte ProQR Therapeutics Sagimet Biosciences Aerovate Therapeutics Coeptis Therapeutics (NASDAQ:COEP) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends. Is COEP or IMMP more profitable? Prima BioMed's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -201.73% -108.46% Prima BioMed N/A N/A N/A Do analysts rate COEP or IMMP? Prima BioMed has a consensus price target of $7.00, suggesting a potential upside of 324.24%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Prima BioMed is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of COEP or IMMP? 13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, COEP or IMMP? Coeptis Therapeutics has a beta of -0.57, indicating that its share price is 157% less volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Which has higher valuation & earnings, COEP or IMMP? Coeptis Therapeutics has higher earnings, but lower revenue than Prima BioMed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.12Prima BioMed$5.14M47.12-$39.78MN/AN/A Does the media favor COEP or IMMP? In the previous week, Coeptis Therapeutics had 2 more articles in the media than Prima BioMed. MarketBeat recorded 2 mentions for Coeptis Therapeutics and 0 mentions for Prima BioMed. Coeptis Therapeutics' average media sentiment score of 0.84 beat Prima BioMed's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Coeptis Therapeutics Positive Prima BioMed Neutral SummaryPrima BioMed beats Coeptis Therapeutics on 7 of the 12 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.29M$3.12B$5.77B$9.91BDividend YieldN/A2.29%6.71%4.52%P/E Ratio-2.1220.9775.5426.08Price / SalesN/A290.04480.4288.30Price / CashN/A44.9736.9659.01Price / Book7.629.8611.446.09Net Income-$10.88M-$53.47M$3.28B$266.14M7 Day Performance-7.88%2.92%0.96%0.44%1 Month Performance10.64%9.83%7.83%4.55%1 Year Performance230.73%15.97%62.64%26.15% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics1.3237 of 5 stars$12.27+3.2%N/A+231.6%$57.29MN/A-2.122Short Interest ↓Gap UpIMMPPrima BioMed0.9161 of 5 stars$1.69-0.6%$7.00+314.2%-35.8%$248.08M$5.14M0.002,021EDITEditas Medicine4.1545 of 5 stars$2.73+0.4%$5.10+86.8%-20.9%$245.48M$32.31M-0.96230Trending NewsAnalyst ForecastAnalyst RevisionTKNOAlpha Teknova2.8628 of 5 stars$4.57+2.0%$10.00+118.8%-4.8%$244.56M$38.92M-10.88240FENCAdherex Technologies1.8907 of 5 stars$8.68+0.3%$13.33+53.6%+67.6%$241.39M$47.54M-20.6710ALECAlector3.9327 of 5 stars$2.36+0.9%$4.17+76.6%-33.4%$238.86M$81.13M-2.03270News CoveragePositive NewsAnalyst DowngradeANNXAnnexon2.4949 of 5 stars$2.15flat$12.50+481.4%-62.7%$236.26MN/A-1.6760News CoveragePositive NewsHUMAHumacyte2.7961 of 5 stars$1.47-2.0%$10.64+624.0%-73.9%$232.81M$818K-3.27150Positive NewsPRQRProQR Therapeutics2.7146 of 5 stars$2.20-2.2%$8.00+263.6%+30.0%$231.47M$16.49M-4.78180SGMTSagimet Biosciences3.4245 of 5 stars$7.07-0.1%$25.67+263.0%+166.3%$229.92M$2M-3.868Positive NewsAnalyst UpgradeAVTEAerovate TherapeuticsN/A$7.90-4.0%N/A-88.5%$228.98MN/A-2.6420News CoveragePositive NewsHigh Trading Volume Related Companies and Tools Related Companies Prima BioMed Alternatives Editas Medicine Alternatives Alpha Teknova Alternatives Adherex Technologies Alternatives Alector Alternatives Annexon Alternatives Humacyte Alternatives ProQR Therapeutics Alternatives Sagimet Biosciences Alternatives Aerovate Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 9/6/2025 by MarketBeat.com Staff From Our Partners6-Figure Target for BTC by 2025Crypto ETF records broken – here's what’s next The biggest names in finance have built the infrastructure f...Crypto 101 Media | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
